Background: On February 2021, Peru began the vaccination process against SARS-CoV-2 using the authorized BBIBP-CorV vaccine on healthcare workers (HW) giving their increased exposition to the virus. However, until date there is few data available regarding the effectiveness of this vaccine among this population. Our study aims to evaluate the effectiveness of the BBIBP-CorV vaccine to prevent infection and death in health care workers in Peru. Methods: We did a retrospective cohort study, since February 9 to June 30, 2021, and included people identified in the updated national registry of HW provided by the Ministry of Health (MoH). We calculated vaccine effectiveness to prevent three outcomes: laboratory-confirmed SARS-CoV-2 infection by Rt-PCR or antigen test, COVID-19 related mortality, and all-cause mortality among those partially immunized (=14 days after receiving their first dose and 14 days before receiving the second dose) and fully immunized (=14 days after receiving their second dose). We used the extension of Cox proportional-hazards regression to model mortality outcomes, and a Poisson regression to model SARS-CoV-2 infection, allowing in each case time-varying immunization status of the subjects included in the study. Findings: Between Feb 9, and June 30, 2021, 606,772 HW were eligible to the study, 396,440 (66%) were female and have a median age of 44 (IQR: 33·0, 51·0). In fully immunized HW adjusted vaccine effectiveness was 83.6 (95% CI 80.2 to 86.4) to prevent all-causes mortality, 88.7 (95% CI 85.1 to 91.4) to prevent COVID-19 mortality and 40.3 (95% CI 38.9 to 41.6) to preventing SARS-CoV-2 infection. Among those partially immunized the estimated effectiveness was 42.4 (95% CI 31.9 to 51.3) to prevent all-causes mortality, 34.3 (95% CI 20.3 to 45.9) to prevent COVID-19 mortality, and 40.3 (95% CI 38.9 to 41.6) to prevent SARS-CoV-2 infection respectively. Interpretation: Inactivated SARS-CoV-2 BBIBP-CorV vaccine have shown to be effective to prevent all-cause mortality, COVID-19 mortality, and of SARS-CoV-2 infection in partially and fully immunized Peruvian healthcare workers.